NRPa-308

NRPa-308 (compound 2a) (10-42 μM; 1-2 h) inhibits VEGF-A₁₆₅ binding to purified NRP-1 protein with an IC₅₀ of 42 μM, and achieves 32% inhibition at a concentration of 10 μM^[1].
NRPa-308 (0.2 μM; 72 h) reduces adhesion of HUVEC with an IC₅₀ of 0.2 μM^[1].
NRPa-308 (72 h) inhibits adhesion and viability of HUVEC (IC₅₀ = 0.2 μM) as well as adhesion of MDA-MB-231 human breast cancer cells (IC₅₀ = 0.5 μM)^[1].
NRPa-308 (72 h) reduces viability of native, Shcontrol-modified, and ShVEGF-R2-modified MDA-MB-231 human breast cancer cells with IC₅₀ values of 0.6 μM, 0.8 μM, and 0.9 μM respectively, but loses potency (IC₅₀ = 9.0 μM) on ShNRP-1-modified MDA-MB-231 cells following 72 h of treatment^[1].
NRPa-308 (24-72 h) reduces viability of most tested human solid and haematological cancer cell lines with IC₅₀ values ranging from 0.10 μM to 0.60 μM after 72 h treatment, shows weaker potency against normal human fibroblasts and lymphatic endothelial cells (IC₅₀ = 20.8 μM and 11.2 μM respectively), and exhibits no effect (IC₅₀ ≥ 10 μM) on select solid and haematological cancer cell lines^[1].
NRPa-308 (0.2 μM; 24 h) dramatically inhibits tubule formation and significantly reduces the migratory speed of VEGF-A165-stimulated HUVEC and MDA-MB-231 human breast cancer cells following 24 h of incubation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.